Patents Assigned to ImClone LLC
-
Patent number: 10766961Abstract: The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.Type: GrantFiled: August 11, 2015Date of Patent: September 8, 2020Assignee: ImClone LLCInventors: Paolo B. Abada, Shao-Chun Chang, Yanzhi Hsu, Ling Yang
-
Publication number: 20180207268Abstract: The present invention relates to a combination of an anti-human VEGFR2 antibody, preferably ramucirumab, and N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2- dihydropyridine-3-carboxamide, and to methods of using the combination to treat certain disorders, such as gastric cancer.Type: ApplicationFiled: August 10, 2016Publication date: July 26, 2018Applicant: ImClone LLCInventors: Sudhakar R. CHINTHARLAPALLI, Anthony S. FISCHL, Victoria Lynn PEEK, Richard A. WALGREN, Sau Chi Betty YAN
-
Publication number: 20170333554Abstract: The invention provides for a dosing regimen for human antibodies that bind to human platelet-derived growth factor receptor alpha (PDGFR alpha), preferably olaratumab.Type: ApplicationFiled: May 9, 2017Publication date: November 23, 2017Applicant: IMCLONE, LLCInventors: John Robert BALDWIN, Ilaria CONTI, Damien Michel CRONIER, Robert Leslie ILARIA, Jr., Zhi Lin MO
-
Publication number: 20170226212Abstract: The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma in patients having levels of alpha-fetoprotein (AFP) of 1.5 ULN or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.Type: ApplicationFiled: August 11, 2015Publication date: August 10, 2017Applicant: IMCLONE, LLCInventors: Paolo B. Abada, Shao-Chun Chang, Yanzhi Hsu, Ling Yang
-
Publication number: 20170137523Abstract: The invention provides for the human antibodies that bind to human platelet-derived growth factor receptor alpha (PDGFR alpha), preferably olaratumab, for the treatment of gastrointestinal stromal tumors with PDGFR alpha mutations including D842V.Type: ApplicationFiled: June 26, 2015Publication date: May 18, 2017Applicant: ImClone LLCInventor: Gaurav D. SHAH
-
Publication number: 20170129958Abstract: Combination of human antibodies that bind to human platelet-derived growth factor receptor alpha (PDGFR alpha), preferably olaratumab, and doxorubicin as a medicament for the treatment of soft tissue sarcoma.Type: ApplicationFiled: June 26, 2015Publication date: May 11, 2017Applicant: ImClone LLCInventors: Nick LOIZOS, Gaurav D. SHAH
-
Patent number: 9375488Abstract: The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.Type: GrantFiled: December 11, 2014Date of Patent: June 28, 2016Assignees: ImClone, LLC, ImmunoGen, Inc.Inventors: Paul J. Balderes, Scott W. Eastman, Hans K. Erickson, Dale L. Ludwig, Christopher M. Moxham, Gregory D. Plowman, Alan C. Rigby
-
Publication number: 20150165067Abstract: The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.Type: ApplicationFiled: December 11, 2014Publication date: June 18, 2015Applicants: IMCLONE LLC, IMMUNOGEN, INC.Inventors: Paul J. BALDERES, Scott W. EASTMAN, Hans K. ERICKSON, Dale L. LUDWIG, Christopher M. MOXHAM, Gregory D. PLOWMAN, Alan C. RIGBY
-
Patent number: 8784818Abstract: The present invention provides anti-VEGFR-3 monoclonal antibodies, pharmaceutical compositions containing said antibodies and uses of said antibodies in the treatment of disease.Type: GrantFiled: May 7, 2013Date of Patent: July 22, 2014Assignee: ImClone LLCInventors: Bronislaw Pytowski, Krishnadatt Persaud, Nathalie Zayek
-
Patent number: 8574578Abstract: The invention provides antibodies that bind to human PDGFR? and neutralize activation of the receptor. The invention further provides methods for neutralizing activation of PDGFR? and methods of treating a mammal with a neoplastic disease using the antibodies alone or in combination with other agents.Type: GrantFiled: October 19, 2011Date of Patent: November 5, 2013Assignee: ImClone LLCInventors: Nick Loizos, Jim Huber
-
Patent number: 8552157Abstract: This invention is directed to antibodies that specifically bind to an extracellular domain of human c-Kit, pharmaceutical compositions comprising these antibodies, and their use in treating cancer.Type: GrantFiled: May 3, 2012Date of Patent: October 8, 2013Assignee: ImClone LLCInventors: Michael Amatulli, Laura Ann Breen (nee Brennan), Keren Paz
-
Patent number: 8481034Abstract: The present invention provides anti-VEGFR-3 monoclonal antibodies, pharmaceutical compositions containing said antibodies and uses of said antibodies in the treatment of disease.Type: GrantFiled: September 1, 2011Date of Patent: July 9, 2013Assignee: ImClone, LLCInventors: Bronislaw Pytowski, Krishnadatt Persaud, Nathalie Zayek
-
Patent number: 8425911Abstract: The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering a PDGFR alpha antagonist. The invention further provides methods of treating a mammal with a neoplastic disease using the antibodies alone or in combination with other agents.Type: GrantFiled: October 19, 2011Date of Patent: April 23, 2013Assignees: ImClone LLC, Philadelphia Health and Education CorporationInventors: Nick Loizos, Alessandro Fatatis, Nathan Graeme Dolloff
-
Patent number: 8404240Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.Type: GrantFiled: April 20, 2012Date of Patent: March 26, 2013Assignee: ImClone LLCInventor: Haijun Sun
-
Publication number: 20120288506Abstract: This invention is directed to antibodies that specifically bind to an extracellular domain of human c-Kit, pharmaceutical compositions comprising these antibodies, and their use in treating cancer.Type: ApplicationFiled: May 3, 2012Publication date: November 15, 2012Applicant: ImClone LLCInventors: Michael Amatulli, Laura Ann Breen (nee Brennan), Keren Paz
-
Patent number: 8263079Abstract: The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.Type: GrantFiled: March 28, 2011Date of Patent: September 11, 2012Assignee: ImClone, LLCInventors: Jacqueline Francoise Doody, Yanxia Li
-
Patent number: 8263074Abstract: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing FGFR-1 or FGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.Type: GrantFiled: December 16, 2011Date of Patent: September 11, 2012Assignee: ImClone LLCInventors: Haijun Sun, Juqun Shen, James Robert Tonra
-
Publication number: 20120219563Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.Type: ApplicationFiled: April 20, 2012Publication date: August 30, 2012Applicant: IMCLONE LLCInventor: Haijun SUN
-
Publication number: 20120177666Abstract: The present invention is directed to antibodies against human transforming growth factor beta receptor II (TGF?RII), pharmaceutical compositions comprising antibodies and methods of using the antibodies, alone or in combination, for example, for treating cancer and fibrosis.Type: ApplicationFiled: February 20, 2012Publication date: July 12, 2012Applicant: IMCLONE LLCInventor: Yan WU
-
Patent number: 8182815Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.Type: GrantFiled: September 19, 2011Date of Patent: May 22, 2012Assignee: ImClone, LLCInventors: Haijun Sun, Ling Liu